Finally, a novel classification of MM based on different molecular profiles, gene alterations (including Bap1 mutated status) and survival outcomes, confirmed at the molecular level that dysregulated EMT is an important parameter to differentiate the two subgroups identified [87]. Here, BAP1 is linked to Miyoshi myopathy.